Cardiotoxicity of chemotherapy and targeted agents
- PMID: 33948350
- PMCID: PMC8085845
Cardiotoxicity of chemotherapy and targeted agents
Abstract
The evolution of cancer treatment and development of new classes of anticancer therapies have continued to revolutionize the field of oncology. New therapies including targeted agents, immunotherapies, and adoptive cell transfer have allowed for exciting survival benefit progress for patients. However, the novel nature of these therapies as well as the longer survival periods of patients receiving them has highlighted the various side effects of anticancer therapies. Cardiotoxicity has emerged as a major side effect of anticancer treatment and can present both acutely during treatment and chronically even years after treatment has been completed. This work compiles the cardiotoxic side effects of various chemotherapeutic and targeted anticancer therapies and their management.
Keywords: Cardiotoxicity; angina; chemotherapy; targeted agents.
AJCR Copyright © 2021.
Conflict of interest statement
None.
Similar articles
-
The Growing Impact of Cardiovascular Oncology: Epidemiology and Pathophysiology.Semin Thromb Hemost. 2021 Nov;47(8):899-906. doi: 10.1055/s-0041-1729885. Epub 2021 Jul 12. Semin Thromb Hemost. 2021. PMID: 34255338 Review.
-
Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection.Front Cardiovasc Med. 2022 Apr 15;9:847012. doi: 10.3389/fcvm.2022.847012. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35497981 Free PMC article. Review.
-
Cardiotoxicity of Novel Targeted Chemotherapeutic Agents.Curr Treat Options Cardiovasc Med. 2018 Jun 19;20(7):53. doi: 10.1007/s11936-018-0649-4. Curr Treat Options Cardiovasc Med. 2018. PMID: 29922881 Review.
-
Cardio-oncology: A Focus on Cardiotoxicity.Eur Cardiol. 2018 Aug;13(1):64-69. doi: 10.15420/ecr.2017:17:2. Eur Cardiol. 2018. PMID: 30310475 Free PMC article. Review.
-
Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system.Crit Rev Oncol Hematol. 2018 Jun;126:186-200. doi: 10.1016/j.critrevonc.2018.03.014. Epub 2018 Mar 29. Crit Rev Oncol Hematol. 2018. PMID: 29759560 Review.
Cited by
-
Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies.Pharmaceuticals (Basel). 2022 Aug 16;15(8):1007. doi: 10.3390/ph15081007. Pharmaceuticals (Basel). 2022. PMID: 36015155 Free PMC article. Review.
-
Cardiotoxicity in Cancer Patients: The Prevalence, Risk Factors, and Cardioprotective Measures in a Cancer Centre in Saudi Arabia.Cureus. 2024 May 3;16(5):e59608. doi: 10.7759/cureus.59608. eCollection 2024 May. Cureus. 2024. PMID: 38832203 Free PMC article.
-
Traditional Chinese medicine as a protective strategy against chemotherapy-induced cardiotoxicity: An overview of the literature.J Tradit Complement Med. 2024 Jun 22;15(2):107-118. doi: 10.1016/j.jtcme.2024.06.010. eCollection 2025 Mar. J Tradit Complement Med. 2024. PMID: 40060147 Free PMC article. Review.
-
Anticancer Drug-Induced Cardiotoxicity: Insights and Pharmacogenetics.Pharmaceuticals (Basel). 2021 Sep 25;14(10):970. doi: 10.3390/ph14100970. Pharmaceuticals (Basel). 2021. PMID: 34681194 Free PMC article. Review.
-
Cardiotoxicity induced by chemotherapy and immunotherapy in cancer treatment: a bibliometric analysis.Discov Oncol. 2025 Mar 23;16(1):376. doi: 10.1007/s12672-025-02146-6. Discov Oncol. 2025. PMID: 40121610 Free PMC article.
References
-
- Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. Circ Res. 2016;118:1008–1020. - PubMed
-
- Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64:938–945. - PubMed
-
- Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19:e447–e458. - PubMed
Publication types
LinkOut - more resources
Full Text Sources